Quest Diagnostics shares hit a 52-week high of $248.84, driven by robust demand for specialized testing and strategic expansion that leaves rival Labcorp trailing in annual performance.
Quest Diagnostics is outperforming the Nasdaq with strong volume growth and raised guidance, indicating bullish momentum.
Labcorp has lagged Quest Diagnostics in stock performance, but remains positive on a YTD basis.
The Nasdaq Composite is used as a benchmark, showing lower gains compared to DGX.
Quest Diagnostics (DGX) has surged 41.1% year-to-date, significantly outperforming the Nasdaq Composite's 16.7% gain. The diagnostic leader's momentum is fueled by double-digit volume growth in advanced testing, including Alzheimer's and cardiometabolic panels, leading to raised full-year guidance.
The stock's performance is driven by steady growth in routine testing and rapid expansion in high-margin advanced diagnostics, alongside strategic acquisitions and raised full-year guidance.